HISTORY

Aquavit Pharmaceuticals, Inc. was founded in 2010 in New York City. In the last few years, we have developed several innovative products and IP for personalized medicine. We successfully completed several seed rounds with increased value in stock and focused on proof of concept, pilot commercialization to industry experts and building and expanding our intellectual property. Our mission is to modernize and personalize healthcare for patients through innovative drug and biologics delivery systems. Aquavit has a strong Intellectual Property portfolio, consisting of over 30 patents out of which over 20 are in the U.S., and over 25 trademarks. 


One of Aquavit's innovations is a patented micro-channel® technology - a novel route of administration (RoA) for drugs and biologics. Micro-channel® technology allows for interdermal delivery, which has higher efficacy and speed of delivery for any drug or therapeutic agent currently delivered either topically or via a patch form. Application for micro-channel® technology range from medical aesthetics, dermatology, to oncology.

KEY MILESTONES


2010

Founded in New York City, October 20, 2010


2011

Corporate Strategic and Scientific Advisory Board established

PITO-001 patent submission

IBX-001/SBX-012 alpha formulation developed

Pre-IDE FDA submission completed


2012

IBX-001/SBX-012 505(b)2 regulatory pathway developed

IBX-001/SBX-012 beta formulation developed

IBX-001/SBX-012 first prototype developed

IBX-001/SBX-012 formulation patent submitted

PITO-001 first prototype developed


2013

15 Additional Patents Filed

AQT-001/002 developed

Big data platform Licensing Agreement with Dassault Systemes (Accelrys)

IBX-001 stability testing completed


2014

AQUAGOLD® fine touch™ (AQT-001) pilot launch at American Academy of Dermatology 

AQUAGOLD® smart touch™ (AQX-808) prototype developed 

MOU signed with Mayor of Daegu city, South Korea for collaboration and investment

Manufacturing facility established in Daegu in collaboration with Kyungbuk University


2015

PITO-001 patent granted in South Korea


2016

PITO-001 patent granted and issued in Europe

AQT series FDA Compliance clearance received

Opening Keynote Speaker Company at Big Data Analytics and Pharma Conference


2017

PITO-001 patent granted and issued in US

Received iMicrotox™ (AQB-121) trial IRB approval

AQT-004 regulatory pathway established

IBX series formulation patent granted

AQT-003/004 developed

FDA inspection successfully completed

RFD submitted to FDA for combination with AQT series

First consumer product A.S.A.P!™ Micro Infusion System commercial ready

Skinworkout™ System (Clean.Absolutely. brands) developed

Acquisition of new GMP manufacturing facility


2018

Positive interim data for iMicrotox™ trial

Positive test results of "micro" anesthesia

Jill Waibel, MD joins Aquavit


2019

Successful legal action against counterfeiters

AQR-924 (AQUABELO) patent filed

Active in/out licensing discussions

ACK-122/BCC-903 development initiated

FDA site inspection completed

Acquisition of 2nd GMP manufacturing facility

PITO-002 prototype completed

Company presentation at BIO International Conference

Marc Toulemonde joins as Corporate Advisory Board member

Christopher Cox joins as Corporate Advisory Board member

 

©2010-2020 by Aquavit Pharmaceuticals, Inc. Privacy and Terms.